Eledon Pharmaceuticals (ELDN) Shares Outstanding (Weighted Average) (2013 - 2026)

Eledon Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $112.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 45.77% year-over-year to $112.4 million; the trailing twelve-month figure through Mar 2026 stood at $112.4 million (up 45.77% YoY), and the FY2025 full-year result was $51.8 million, up 6.67% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $112.4 million, up from $51.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $112.4 million in Q1 2026, with the low at $14.3 million in Q2 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $42.3 million across 5 years, with a median of $30.0 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) dropped 3.76% — and 2025, when it soared 157.18%.
• Eledon Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $14.3 million in 2022, then surged by 72.34% to $24.6 million in 2023, then jumped by 97.18% to $48.5 million in 2024, then increased by 6.67% to $51.8 million in 2025, then soared by 117.11% to $112.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $112.4 million (Q1 2026), $51.8 million (Q4 2025), and $77.2 million (Q3 2025), per Business Quant data.